Center for Molecular and Translational Human Infectious Diseases Research, The Houston Methodist Research Institute, Houston, Texas, USA.
Infect Immun. 2014 May;82(5):1744-54. doi: 10.1128/IAI.01639-13. Epub 2014 Feb 10.
Despite the public health challenges associated with the emergence of new pathogenic bacterial strains and/or serotypes, there is a dearth of information regarding the molecular mechanisms that drive this variation. Here, we began to address the mechanisms behind serotype-specific variation between serotype M1 and M3 strains of the human pathogen Streptococcus pyogenes (the group A Streptococcus [GAS]). Spatially diverse contemporary clinical serotype M3 isolates were discovered to contain identical inactivating mutations within genes encoding two regulatory systems that control the expression of important virulence factors, including the thrombolytic agent streptokinase, the protease inhibitor-binding protein-G-related α2-macroglobulin-binding (GRAB) protein, and the antiphagocytic hyaluronic acid capsule. Subsequent analysis of a larger collection of isolates determined that M3 GAS, since at least the 1920s, has harbored a 4-bp deletion in the fasC gene of the fasBCAX regulatory system and an inactivating polymorphism in the rivR regulator-encoding gene. The fasC and rivR mutations in M3 isolates directly affect the virulence factor profile of M3 GAS, as evident by a reduction in streptokinase expression and an enhancement of GRAB expression. Complementation of the fasC mutation in M3 GAS significantly enhanced levels of the small regulatory RNA FasX, which in turn enhanced streptokinase expression. Complementation of the rivR mutation in M3 GAS restored the regulation of grab mRNA abundance but did not alter capsule mRNA levels. While important, the fasC and rivR mutations do not provide a full explanation for why serotype M3 strains are associated with unusually severe invasive infections; thus, further investigation is warranted.
尽管新的致病性细菌菌株和/或血清型的出现带来了公共卫生挑战,但对于驱动这种变异的分子机制的信息却很少。在这里,我们开始研究人类病原体化脓链球菌(A 组链球菌)M1 和 M3 血清型之间血清型特异性变异的机制。具有空间差异的当代临床 M3 分离株被发现,其编码两种调节系统的基因内存在相同的失活突变,这两个调节系统控制着重要毒力因子的表达,包括溶栓剂链激酶、蛋白酶抑制剂结合蛋白-G 相关 α2-巨球蛋白结合(GRAB)蛋白和抗吞噬性透明质酸荚膜。对更大规模分离株集的后续分析表明,自 20 世纪 20 年代以来,M3 GAS 就一直携带 fasBCAX 调节系统 fasC 基因中的 4 个碱基对缺失和 rivR 调节因子编码基因中的失活多态性。M3 分离株中 fasC 和 rivR 突变直接影响 M3 GAS 的毒力因子谱,这表现在链激酶表达减少和 GRAB 表达增强。M3 GAS fasC 突变的互补显著增强了小调控 RNA FasX 的水平,进而增强了链激酶的表达。M3 GAS rivR 突变的互补恢复了 grab mRNA 丰度的调节,但并未改变荚膜 mRNA 水平。虽然 fasC 和 rivR 突变很重要,但它们并不能完全解释为什么 M3 血清型菌株与异常严重的侵袭性感染有关;因此,需要进一步研究。